PCSK9 and cancer: The main cardiovascular outcomes trials, which will be discussed in the next paragraph, called Evaluation of Cardiovascular Outcomes After an ACS During Treatment With Alirocumab (ODYSSEY) [53] and Further CV Outcomes Research with PCSK9 Inhibition In subjects With Elevated Risk (FOURIER) [54], analyzed cardiovascular benefits of PCSK9 inhibitors in non-cancer patients, and recruited mostly only white patients.